Natural Killer Cells Therapeutics Market by Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others), and End User (Research Centers & Institutes, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 2018–2026
Natural killer (NK) cell is a component of innate immunity system that targets cancer cells, and can be used as a therapeutic agent. NK cells target the cells losing MHC-I in cancer, a phenotype that is similar to certain cells in immune-privileged sites whose milieus are separated from peripheral blood.
The global natural killer cell therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.
The growth of the global natural killer cell therapeutics market is driven by rise in use of NK cells to treat cancer, infections, and liver diseases. Moreover, NK cells play vital role in tumor immune-surveillance, which has significantly boosted their adoption across the globe. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global natural killer cell therapeutics market growth. However, lack of specificity and poor in-vivo survival of the cells limit the growth of the market. Furthermore, higher costs associated with the therapies and adverse side effects are expected to hamper the market growth in the coming years. Conversely, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to offer lucrative opportunities for the market.
The global natural killer cell therapeutics market is segmented based on therapeutics, application, end user, and region. Depending on therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies. By application, it is categorized into cancer, gastrointestinal diseases, immunoproliferative disorders, and others. On the basis of end user, it is segregated into hospitals, research centers & institutes, and others. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
The global natural killer cell therapeutics market was valued at $1,402 million in 2018, and is projected to reach $5,096 million by 2026, registering a CAGR of 17.4% from 2019 to 2026.
The growth of the global natural killer cell therapeutics market is driven by rise in use of NK cells to treat cancer, infections, and liver diseases. Moreover, NK cells play vital role in tumor immune-surveillance, which has significantly boosted their adoption across the globe. In addition, rise in awareness among the population regarding various immunotherapies and increase in R&D for the development of bi-specific antibody for engaging NK cells to eliminate tumor cells propel the global natural killer cell therapeutics market growth. However, lack of specificity and poor in-vivo survival of the cells limit the growth of the market. Furthermore, higher costs associated with the therapies and adverse side effects are expected to hamper the market growth in the coming years. Conversely, significant surge in R&D activities toward development of immunotherapy in developing economies is anticipated to offer lucrative opportunities for the market.
The global natural killer cell therapeutics market is segmented based on therapeutics, application, end user, and region. Depending on therapeutics, the natural killer cells therapeutics market is classified into NK cell therapies and NK cell directed antibodies. By application, it is categorized into cancer, gastrointestinal diseases, immunoproliferative disorders, and others. On the basis of end user, it is segregated into hospitals, research centers & institutes, and others. Region wise, it is analyzed across North America, Asia-Pacific, Europe, and LAMEA.
KEY BENEFITS FOR STAKEHOLDERS
- This report entails a detailed quantitative analysis along with the current market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
- The global natural killer cell therapeutics market size and estimations are based on a comprehensive analysis of key developments.
- A qualitative analysis based on innovative products facilitates strategic business planning.
- The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
- By Therapeutics
- NK Cell Therapies
- NK Cell Directed Antibodies
- By Application
- Cancer
- Gastrointestinal Diseases
- Immunoproliferative Disorders
- Others
- By End User
- Research Centers & Institutes
- Hospitals
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Affimed N.V.
- Celgene Corporation
- Fate Therapeutics
- Fortress Biotech
- Glycostem Therapeutics BV
- Innate Pharma S.A.
- Nantkwest Inc.
- Nkarta Therapeutics, Inc.
- NKT Therapeutics Inc.
- Ziopharm Oncology Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of cancer across the globe
3.5.1.2. Increase in government expenditure on healthcare
3.5.1.3. Surge in awareness regarding immunotherapy
3.5.2. Restraints
3.5.2.1. High cost of cancer immunotherapy treatment
3.5.2.2. Stringent government regulations toward approval of immunotherapy
3.5.3. Opportunity
3.5.3.1. Surge in R&D activities toward the development of immunotherapy
3.6. Government regulatory scenerio
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.6.4. Thailand
3.6.5. Singapore
3.6.6. Malaysia
3.6.7. Mexico
3.6.8. Australia
CHAPTER 4: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS
4.1. Overview
4.1.1. Market and forecast
4.2. Natural killer cell therapies
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.3.1. CNDO-109
4.2.3.2. oNKord
4.2.3.3. Natural Killer Cells
4.2.3.4. Others
4.3. NK cell-directed antibodies
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.3.1. MOGAMULIZUMAB
4.3.3.2. Lirilumab
4.3.3.3. AFM13
4.3.3.4. NKTT
4.3.3.5. Others
CHAPTER 5: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast, by region
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Gastrointestinal diseases
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Immunoproliferative disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
CHAPTER 6: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market and forecast
6.2. Research centers and institutes
6.2.1. Market and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospitals and clinics
6.3.1. Market and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by therapeutics
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by therapeutics
7.2.5.2. U.S. market size and forecast, by application
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by therapeutics
7.2.5.5. Canada market size and forecast, by application
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by therapeutics
7.2.5.8. Mexico market size and forecast, by application
7.2.5.9. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast, by therapeutics
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. UK market size and forecast, by therapeutics
7.3.5.2. UK market size and forecast, by application
7.3.5.3. UK market size and forecast, by end user
7.3.5.4. Germany market size and forecast, by therapeutics
7.3.5.5. Germany market size and forecast, by application
7.3.5.6. Germany market size and forecast, by end user
7.3.5.7. France market size and forecast, by therapeutics
7.3.5.8. France market size and forecast, by application
7.3.5.9. France market size and forecast, by end user
7.3.5.10. Italy market size and forecast, by therapeutics
7.3.5.11. Italy market size and forecast, by application
7.3.5.12. Italy market size and forecast, by end user
7.3.5.13. Spain market size and forecast, by therapeutics
7.3.5.14. Spain market size and forecast, by application
7.3.5.15. Spain market size and forecast, by end user
7.3.5.16. Rest of Europe market size and forecast, by therapeutics
7.3.5.17. Rest of Europe market size and forecast, by application
7.3.5.18. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by therapeutics
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan market size and forecast, by therapeutics
7.4.5.2. Japan market size and forecast, by application
7.4.5.3. Japan market size and forecast, by end user
7.4.5.4. China market size and forecast, by therapeutics
7.4.5.5. China market size and forecast, by application
7.4.5.6. China market size and forecast, by end user
7.4.5.7. Australia market size and forecast, by therapeutics
7.4.5.8. Australia market size and forecast, by application
7.4.5.9. Australia market size and forecast, by end user
7.4.5.10. India market size and forecast, by therapeutics
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.5.14. Rest of Asia-Pacific market size and forecast, by application
7.4.5.15. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by therapeutics
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by therapeutics
7.5.5.2. Brazil market size and forecast, by application
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. Saudi Arabia market size and forecast, by therapeutics
7.5.5.5. Saudi Arabia market size and forecast, by application
7.5.5.6. Saudi Arabia market size and forecast, by end user
7.5.5.7. South Africa market size and forecast, by therapeutics
7.5.5.8. South Africa market size and forecast, by application
7.5.5.9. South Africa market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by therapeutics
7.5.5.11. Rest of LAMEA market size and forecast, by application
7.5.5.12. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. AFFIMED N.V.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CELGENE CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. FATE THERAPEUTICS INC.
8.3.1. Company overview
8.3.2. Operating business segments
8.3.3. Product portfolio
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. FORTRESS BIOTECH
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. GLYCOSTEM THERAPEUTICS BV
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. INNATE PHARMA SA
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NANTKWEST INC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. NKARTA THERAPEUTICS, INC.
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Product portfolio
8.8.4. Key strategic moves and developments
8.9. NKT THERAPEUTICS INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. ZIOPHARM ONCOLOGY INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.1.1. Rise in incidence of cancer across the globe
3.5.1.2. Increase in government expenditure on healthcare
3.5.1.3. Surge in awareness regarding immunotherapy
3.5.2. Restraints
3.5.2.1. High cost of cancer immunotherapy treatment
3.5.2.2. Stringent government regulations toward approval of immunotherapy
3.5.3. Opportunity
3.5.3.1. Surge in R&D activities toward the development of immunotherapy
3.6. Government regulatory scenerio
3.6.1. U.S.
3.6.2. Europe
3.6.3. Japan
3.6.4. Thailand
3.6.5. Singapore
3.6.6. Malaysia
3.6.7. Mexico
3.6.8. Australia
CHAPTER 4: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS
4.1. Overview
4.1.1. Market and forecast
4.2. Natural killer cell therapies
4.2.1. Key market trends and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.2.3.1. CNDO-109
4.2.3.2. oNKord
4.2.3.3. Natural Killer Cells
4.2.3.4. Others
4.3. NK cell-directed antibodies
4.3.1. Key market trends and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market analysis, by country
4.3.3.1. MOGAMULIZUMAB
4.3.3.2. Lirilumab
4.3.3.3. AFM13
4.3.3.4. NKTT
4.3.3.5. Others
CHAPTER 5: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY APPLICATION
5.1. Overview
5.1.1. Market size and forecast, by region
5.2. Cancer
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. Gastrointestinal diseases
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
5.4. Immunoproliferative disorders
5.4.1. Market size and forecast, by region
5.4.2. Market analysis, by country
5.5. Others
5.5.1. Market size and forecast
5.5.2. Market analysis, by country
CHAPTER 6: NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER
6.1. Overview
6.1.1. Market and forecast
6.2. Research centers and institutes
6.2.1. Market and forecast, by region
6.2.2. Market analysis, by country
6.3. Hospitals and clinics
6.3.1. Market and forecast, by region
6.3.2. Market analysis, by country
6.4. Others
6.4.1. Market and forecast, by region
6.4.2. Market analysis, by country
CHAPTER 7: NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends and opportunities
7.2.2. Market size and forecast, by therapeutics
7.2.3. Market size and forecast, by application
7.2.4. Market size and forecast, by application
7.2.5. Market size and forecast, by country
7.2.5.1. U.S. market size and forecast, by therapeutics
7.2.5.2. U.S. market size and forecast, by application
7.2.5.3. U.S. market size and forecast, by end user
7.2.5.4. Canada market size and forecast, by therapeutics
7.2.5.5. Canada market size and forecast, by application
7.2.5.6. Canada market size and forecast, by end user
7.2.5.7. Mexico market size and forecast, by therapeutics
7.2.5.8. Mexico market size and forecast, by application
7.2.5.9. Mexico market size and forecast, by end user
7.3. Europe
7.3.1. Key market trends and opportunities
7.3.2. Market size and forecast, by therapeutics
7.3.3. Market size and forecast, by application
7.3.4. Market size and forecast, by end user
7.3.5. Market size and forecast, by country
7.3.5.1. UK market size and forecast, by therapeutics
7.3.5.2. UK market size and forecast, by application
7.3.5.3. UK market size and forecast, by end user
7.3.5.4. Germany market size and forecast, by therapeutics
7.3.5.5. Germany market size and forecast, by application
7.3.5.6. Germany market size and forecast, by end user
7.3.5.7. France market size and forecast, by therapeutics
7.3.5.8. France market size and forecast, by application
7.3.5.9. France market size and forecast, by end user
7.3.5.10. Italy market size and forecast, by therapeutics
7.3.5.11. Italy market size and forecast, by application
7.3.5.12. Italy market size and forecast, by end user
7.3.5.13. Spain market size and forecast, by therapeutics
7.3.5.14. Spain market size and forecast, by application
7.3.5.15. Spain market size and forecast, by end user
7.3.5.16. Rest of Europe market size and forecast, by therapeutics
7.3.5.17. Rest of Europe market size and forecast, by application
7.3.5.18. Rest of Europe market size and forecast, by end user
7.4. Asia-Pacific
7.4.1. Key market trends and opportunities
7.4.2. Market size and forecast, by therapeutics
7.4.3. Market size and forecast, by application
7.4.4. Market size and forecast, by end user
7.4.5. Market size and forecast, by country
7.4.5.1. Japan market size and forecast, by therapeutics
7.4.5.2. Japan market size and forecast, by application
7.4.5.3. Japan market size and forecast, by end user
7.4.5.4. China market size and forecast, by therapeutics
7.4.5.5. China market size and forecast, by application
7.4.5.6. China market size and forecast, by end user
7.4.5.7. Australia market size and forecast, by therapeutics
7.4.5.8. Australia market size and forecast, by application
7.4.5.9. Australia market size and forecast, by end user
7.4.5.10. India market size and forecast, by therapeutics
7.4.5.11. India market size and forecast, by application
7.4.5.12. India market size and forecast, by end user
7.4.5.13. Rest of Asia-Pacific market size and forecast, by therapeutics
7.4.5.14. Rest of Asia-Pacific market size and forecast, by application
7.4.5.15. Rest of Asia-Pacific market size and forecast, by end user
7.5. LAMEA
7.5.1. Key market trends and opportunities
7.5.2. Market size and forecast, by therapeutics
7.5.3. Market size and forecast, by application
7.5.4. Market size and forecast, by end user
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil market size and forecast, by therapeutics
7.5.5.2. Brazil market size and forecast, by application
7.5.5.3. Brazil market size and forecast, by end user
7.5.5.4. Saudi Arabia market size and forecast, by therapeutics
7.5.5.5. Saudi Arabia market size and forecast, by application
7.5.5.6. Saudi Arabia market size and forecast, by end user
7.5.5.7. South Africa market size and forecast, by therapeutics
7.5.5.8. South Africa market size and forecast, by application
7.5.5.9. South Africa market size and forecast, by end user
7.5.5.10. Rest of LAMEA market size and forecast, by therapeutics
7.5.5.11. Rest of LAMEA market size and forecast, by application
7.5.5.12. Rest of LAMEA market size and forecast, by end user
CHAPTER 8: COMPANY PROFILES
8.1. AFFIMED N.V.
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments
8.2. CELGENE CORPORATION
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. FATE THERAPEUTICS INC.
8.3.1. Company overview
8.3.2. Operating business segments
8.3.3. Product portfolio
8.3.4. Business performance
8.3.5. Key strategic moves and developments
8.4. FORTRESS BIOTECH
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Product portfolio
8.4.4. Business performance
8.4.5. Key strategic moves and developments
8.5. GLYCOSTEM THERAPEUTICS BV
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. INNATE PHARMA SA
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.6.6. Key strategic moves and developments
8.7. NANTKWEST INC
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.7.6. Key strategic moves and developments
8.8. NKARTA THERAPEUTICS, INC.
8.8.1. Company overview
8.8.2. Operating business segments
8.8.3. Product portfolio
8.8.4. Key strategic moves and developments
8.9. NKT THERAPEUTICS INC.
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. ZIOPHARM ONCOLOGY INC.
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
8.10.6. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS, 2018–2026 ($MILLION)
TABLE 02. GLOBAL NATURAL KILLER CELL THERAPIES MARKET, BY REGION 2018–2026 ($MILLION)
TABLE 03. GLOBAL NK CELL-DIRECTED ANTIBODIES MARKET, BY REGION 2018–2026 ($MILLION)
TABLE 04. NATURAL KILLER CELL THERAPEUTICS MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 05. CANCER NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 06. NATURAL KILLER CELL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION 2018-2026, ($MILLION)
TABLE 07. NATURAL KILLER CELL THERAPEUTICS MARKET FOR IMMUNOPROLIFERATIVE DISORDERS, BY REGION 2018-2026, ($MILLION)
TABLE 08. NATURAL KILLER CELL THERAPEUTICS MARKET FOR OTHERS, BY REGION 2018-2026, ($MILLION)
TABLE 09. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 10. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY RESEARCH CENTERS AND INSTITUTES, 2018–2026 ($MILLION)
TABLE 11. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY HOSPITALS AND CLINICS, 2018–2026 ($MILLION)
TABLE 12. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY HOSPITALS AND CLINICS, 2018–2026 ($MILLION)
TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET BY REGION, 2018-2026, ($MILLION)
TABLE 14. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018–2026 ($MILLION)
TABLE 15. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 16. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 17. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 18. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 19. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 20. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 21. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 22. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 23. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 24. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 25. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 26. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 27. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 28. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 29. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 30. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 31. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 32. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 33. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 34. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 35. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 36. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 37. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 38. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 39. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 40. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 41. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 42. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 43. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 44. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 45. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 46. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 47. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 48. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 49. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 50. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 51. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 52. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 53. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 54. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 55. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 56. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 57. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 58. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 59. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 60. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 61. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 62. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 63. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 64. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 68. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 69. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 70. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 71. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 72. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 73. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 74. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 75. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 76. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 77. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 78. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 79. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 80. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 81. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 82. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 83. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 84. AFFIMED NV: COMPANY SNAPSHOT
TABLE 85. AFFIMED NV: OPERATING SEGMENTS
TABLE 86. AFFIMED NV: PRODUCT PORTFOLIO
TABLE 87. CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 88. CELGENE CORPORATION: PRODUCT SEGMENTS
TABLE 89. CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 90. FATE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 91. FATE THERAPEUTICS: OPERATING SEGMENTS
TABLE 92. FATE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 93. FORTRESS BIOTECH: COMPANY SNAPSHOT
TABLE 94. FORTRESS BIOTECH: PRODUCT PORTFOLIO
TABLE 95. GLYCOSTEM THERAPEUTICS BV: COMPANY SNAPSHOT
TABLE 96. GLYCOSTEM THERAPEUTICS BV: OPERATING SEGMENTS
TABLE 97. GLYCOSTEM THERAPEUTICS BV: PRODUCT PORTFOLIO
TABLE 98. INNATE PHARMA SA: COMPANY SNAPSHOT
TABLE 99. INNATE PHARMA SA: OPERATING SEGMENTS
TABLE 100. INNATE PHARMA SA: PRODUCT PORTFOLIO
TABLE 101. NANTKWEST INC.: COMPANY SNAPSHOT
TABLE 102. NANTKWEST INC.: OPERATING SEGMENTS
TABLE 103. NANTKWEST INC.: PRODUCT PORTFOLIO
TABLE 104. NKARTA THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 105. NKARTA THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 106. NKARTA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 107. NKT THERAPEUTICS INC: COMPANY SNAPSHOT
TABLE 108. NKT THERAPEUTICS INC.: OPERATING SEGMENTS
TABLE 109. NKT THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 110. ZIOPHARM ONCOLOGY INC: COMPANY SNAPSHOT
TABLE 111. ZIOPHARM ONCOLOGY INC: OPERATING SEGMENTS
TABLE 112. ZIOPHARM ONCOLOGY INC.: PRODUCT PORTFOLIO
TABLE 01. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY THERAPEUTICS, 2018–2026 ($MILLION)
TABLE 02. GLOBAL NATURAL KILLER CELL THERAPIES MARKET, BY REGION 2018–2026 ($MILLION)
TABLE 03. GLOBAL NK CELL-DIRECTED ANTIBODIES MARKET, BY REGION 2018–2026 ($MILLION)
TABLE 04. NATURAL KILLER CELL THERAPEUTICS MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 05. CANCER NATURAL KILLER CELL THERAPEUTICS MARKET, BY REGION, 2017–2025 ($MILLION)
TABLE 06. NATURAL KILLER CELL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISEASES, BY REGION 2018-2026, ($MILLION)
TABLE 07. NATURAL KILLER CELL THERAPEUTICS MARKET FOR IMMUNOPROLIFERATIVE DISORDERS, BY REGION 2018-2026, ($MILLION)
TABLE 08. NATURAL KILLER CELL THERAPEUTICS MARKET FOR OTHERS, BY REGION 2018-2026, ($MILLION)
TABLE 09. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY END USER, 2018–2026 ($MILLION)
TABLE 10. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY RESEARCH CENTERS AND INSTITUTES, 2018–2026 ($MILLION)
TABLE 11. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY HOSPITALS AND CLINICS, 2018–2026 ($MILLION)
TABLE 12. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET, BY HOSPITALS AND CLINICS, 2018–2026 ($MILLION)
TABLE 13. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET BY REGION, 2018-2026, ($MILLION)
TABLE 14. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET, BY THERAPEUTICS, 2018–2026 ($MILLION)
TABLE 15. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 16. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 17. NORTH AMERICA NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 18. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 19. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 20. U.S. NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 21. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 22. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 23. CANADA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 24. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 25. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 26. MEXICO NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 27. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 28. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 29. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 30. EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 31. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 32. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 33. UK NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 34. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 35. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 36. GERMANY NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 37. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 38. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 39. FRANCE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 40. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 41. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 42. ITALY NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 43. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 44. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 45. SPAIN NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 46. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 47. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 48. REST OF EUROPE NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 49. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 50. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 51. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 52. ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 53. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 54. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 55. JAPAN NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 56. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 57. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 58. CHINA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 59. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 60. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 61. AUSTRALIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 62. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 63. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 64. INDIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 65. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 66. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 68. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 69. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 70. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 71. LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY COUNTRY, 2018-2026, ($MILLION)
TABLE 72. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 73. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 74. BRAZIL NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 75. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 76. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 77. SAUDI ARABIA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 78. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 79. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 80. SOUTH AFRICA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 81. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY THERAPEUTICS, 2018-2026, ($MILLION)
TABLE 82. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY APPLICATION, 2018-2026, ($MILLION)
TABLE 83. REST OF LAMEA NATURAL KILLER CELL THERAPEUTICS MARKET BY END USER, 2018-2026, ($MILLION)
TABLE 84. AFFIMED NV: COMPANY SNAPSHOT
TABLE 85. AFFIMED NV: OPERATING SEGMENTS
TABLE 86. AFFIMED NV: PRODUCT PORTFOLIO
TABLE 87. CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE 88. CELGENE CORPORATION: PRODUCT SEGMENTS
TABLE 89. CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE 90. FATE THERAPEUTICS: COMPANY SNAPSHOT
TABLE 91. FATE THERAPEUTICS: OPERATING SEGMENTS
TABLE 92. FATE THERAPEUTICS: PRODUCT PORTFOLIO
TABLE 93. FORTRESS BIOTECH: COMPANY SNAPSHOT
TABLE 94. FORTRESS BIOTECH: PRODUCT PORTFOLIO
TABLE 95. GLYCOSTEM THERAPEUTICS BV: COMPANY SNAPSHOT
TABLE 96. GLYCOSTEM THERAPEUTICS BV: OPERATING SEGMENTS
TABLE 97. GLYCOSTEM THERAPEUTICS BV: PRODUCT PORTFOLIO
TABLE 98. INNATE PHARMA SA: COMPANY SNAPSHOT
TABLE 99. INNATE PHARMA SA: OPERATING SEGMENTS
TABLE 100. INNATE PHARMA SA: PRODUCT PORTFOLIO
TABLE 101. NANTKWEST INC.: COMPANY SNAPSHOT
TABLE 102. NANTKWEST INC.: OPERATING SEGMENTS
TABLE 103. NANTKWEST INC.: PRODUCT PORTFOLIO
TABLE 104. NKARTA THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE 105. NKARTA THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE 106. NKARTA THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE 107. NKT THERAPEUTICS INC: COMPANY SNAPSHOT
TABLE 108. NKT THERAPEUTICS INC.: OPERATING SEGMENTS
TABLE 109. NKT THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE 110. ZIOPHARM ONCOLOGY INC: COMPANY SNAPSHOT
TABLE 111. ZIOPHARM ONCOLOGY INC: OPERATING SEGMENTS
TABLE 112. ZIOPHARM ONCOLOGY INC.: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015–2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015–2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015–2018*
FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. MODERATE THREAT OF NEW ENTRANTS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING
FIGURE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13. NK CELL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 14. NK CELL-DIRECTED ANTIBODIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 15. CANCER MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 16. GASTROINTESTINAL DISEASES MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 17. IMMUNOPROLIFERATIVE DISORDERS MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 18. OTHER MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 19. RESEARCH CENTERS AND INSTITUTES THERAPEUTICS MARKET, BY REGION, 2017–2025 ($MILLION)
FIGURE 20. HOSPITALS MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 21. OTHERS MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 22. AFFIMED NV: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. AFFIMED NV: REVENUE SHARE BY REGION, 2018(%)
FIGURE 24. CELGENE CORPORATION: NET SALES, 2016–2018 ($MILLION)
FIGURE 25. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 26. CELGENE CORPORATION: REVENUE SHARE BY REGION, 2018(%)
FIGURE 27. FATE THERAPEUTICS: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. FORTRESS BIOTECH: NET SALES, 2016–2018 ($MILLION)
FIGURE 29. FORTRESS BIOTECH: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30. INNATE PHARMA SA: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. NANTKWEST INC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. ZIOPHARM ONCOLOGY INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 01. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. TOP WINNING STRATEGIES, BY YEAR, 2015–2018*
FIGURE 04. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2015–2018* (%)
FIGURE 05. TOP WINNING STRATEGIES, BY COMPANY, 2015–2018*
FIGURE 06. MODERATE BARGAINING POWER OF BUYERS
FIGURE 07. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 08. MODERATE THREAT OF NEW ENTRANTS
FIGURE 09. MODERATE THREAT OF SUBSTITUTION
FIGURE 10. MODERATE COMPETITIVE RIVALRY
FIGURE 11. TOP PLAYER POSITIONING
FIGURE 12. GLOBAL NATURAL KILLER CELL THERAPEUTICS MARKET: RESTRAINTS, DRIVERS, AND OPPORTUNITY
FIGURE 13. NK CELL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 14. NK CELL-DIRECTED ANTIBODIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 15. CANCER MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 16. GASTROINTESTINAL DISEASES MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 17. IMMUNOPROLIFERATIVE DISORDERS MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 18. OTHER MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 19. RESEARCH CENTERS AND INSTITUTES THERAPEUTICS MARKET, BY REGION, 2017–2025 ($MILLION)
FIGURE 20. HOSPITALS MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 21. OTHERS MARKET BY COUNTRY, 2018-2026, ($MILLION)
FIGURE 22. AFFIMED NV: NET SALES, 2016–2018 ($MILLION)
FIGURE 23. AFFIMED NV: REVENUE SHARE BY REGION, 2018(%)
FIGURE 24. CELGENE CORPORATION: NET SALES, 2016–2018 ($MILLION)
FIGURE 25. CELGENE CORPORATION: REVENUE SHARE BY SEGMENT, 2018(%)
FIGURE 26. CELGENE CORPORATION: REVENUE SHARE BY REGION, 2018(%)
FIGURE 27. FATE THERAPEUTICS: NET SALES, 2016–2018 ($MILLION)
FIGURE 28. FORTRESS BIOTECH: NET SALES, 2016–2018 ($MILLION)
FIGURE 29. FORTRESS BIOTECH: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30. INNATE PHARMA SA: NET SALES, 2016–2018 ($MILLION)
FIGURE 31. NANTKWEST INC.: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. ZIOPHARM ONCOLOGY INC: NET SALES, 2016–2018 ($MILLION)
